Sumitomo Pharma Co Ltd SMDPY

Health CarePharmaceuticalsJapan

Last close 13.50 USD on Nov 1, 2026, +17.9% year to date

Quant rating

Quant rating A+ Rank 3 of 211 in Health Care

Growth B 68 of 211
Valuation B 41 of 211
Quality A 19 of 211
Revisions B 35 of 211
Momentum A 8 of 211

Wall Street consensus Buy (2.14)Average target 14.18 USD +5.1%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 5.4B
Enterprise value: 5.9B
52-week range: 7.84 – 24.48
3-year range: 1.99 – 24.48
Dividend yield: 0.00%
Beta (5 years): –
Shares outstanding: 449M
Next earnings: Oct 30, 2026

About the company

Sumitomo Pharma Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through three geographical segments. The Japan segment is engaged in the manufacture, purchase, and sale of prescription drugs, purchase and sale of medical devices, undertakes development and manufacture in the field of regenerative medicine and cellular medicine, and the manufacture of pharmaceuticals, medical devices, and regenerative medicine products that have been developed through joint development in the field of regenerative medicine. This segment also provides storage and delivery service of pharmaceuticals. The North America segment is engaged in the manufacture, purchase, and sale of prescription drugs. The Asia segment is engaged in the manufacture and sale of prescription drugs (small packaging), and the import, purchase and sale of prescription drugs in Southeast Asia and Taiwan, as well as the provision and collection of information on products.

Growth and profitability

Growth and profitability by fiscal year
	2026	2025	2024	2023	2022	5Y avg
Revenue (mil)	2,856	2,660	2,079	4,184	4,603	–
Revenue growth	7.4%	27.9%	−50.3%	−9.1%	−1.2%	−9.3%
EPS (basic, normalized)	1.70	0.40	−5.07	−1.38	1.10	–
EPS growth	322.4%	–	–	–	–	–
Gross margin	56.7%	61.5%	59.8%	67.9%	71.9%	63.6%
Net margin	23.6%	5.9%	−100.1%	−13.4%	10.1%	−14.8%
ROE	46.3%	14.5%	−111.9%	−14.7%	9.5%	−11.3%

Balance sheet, last quarter
Cash & short-term investments (mil)	538
Current ratio	1.36x
Long-term debt (mil)	760
Net debt (mil)	350
Total equity (mil)	2,739
Net debt / equity	0.13x
Net debt / EBITDA	0.44x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2026 actual	2,856	+7.4%	2.0x	797	+111.9%	7.3x	1.70	+322.4%	7.9x
2027	3,584	+25.5%	1.6x	813	+2.0%	7.2x	1.37	−19.7%	9.9x
2028	4,006	+11.8%	1.5x	899	+10.5%	6.5x	1.40	+2.1%	9.7x
2029	4,030	+0.6%	1.5x	714	−20.5%	8.2x	1.09	−22.3%	12.4x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2027	3,584	+0.3%	+3.0%	+7.7%	1.37	+0.5%	+9.9%	+17.9%
2028	4,006	0.0%	+3.0%	+11.7%	1.40	−0.3%	+14.0%	+9.3%
2029	4,030	0.0%	+1.6%	+4.0%	1.09	−0.2%	+15.5%	−9.3%

Earnings surprises EPS beat in 2 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	79,530	90,675	90,074	112,434	105,649	108,002	119,120	120,624	105,548	129,495
Sales mean (mil)	77,307	82,467	88,034	90,193	88,359	91,096	97,423	102,775	104,467	114,100
Surprise	+2.9%	+10.0%	+2.3%	+24.7%	+19.6%	+18.6%	+22.3%	+17.4%	+1.0%	+13.5%
EPS reported	−496.51	40.11	−121.23	134.53	6.08	28.21	220.63	22.19	−2.04	39.02
EPS mean	−323.99	−2.52	15.00	−2.52	−12.32	19.71	77.14	−1.88	−15.24	–
Surprise	−53.2%	−1,693.6%	−908.3%	−5,444.9%	−149.4%	+43.1%	+186.0%	−1,282.2%	+86.6%	–

Peer comparison Pharmaceuticals

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
SMDPY Sumitomo Pharma Co Ltd	5.4B	0.44x	23.6%	2.07x	9.9x	9.7x	7.2x	6.5x
MANE Veradermics, Incorporated	5.8B	–	–	7.17x	−48.7x	−53.0x	−43.6x	−40.4x
MIRM Mirum Pharmaceuticals, Inc.	5.5B	–	−4.5%	−528.13x	−5.6x	−133.9x	−6.4x	−126.6x
APTX Apotex Health Corp	5.5B	–	10.7%	21.79x	15.4x	14.3x	10.2x	9.4x
PTCT PTC Therapeutics, Inc.	5.0B	0.79x	39.4%	−26.20x	61.2x	27.0x	16.9x	11.4x
HKMPY Hikma Pharmaceuticals PLC	4.8B	–	–	–	20.6x	19.0x	5.6x	5.3x
Mean		0.62x	17.3%	−104.66x	8.8x	−19.5x	−1.7x	−22.4x
Median		0.62x	17.1%	2.07x	12.6x	12.0x	6.4x	5.9x

Technical analysis

1M+29.2%
3M+45.9%
1Y+17.9%
3Y+319.3%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Sumitomo Pharma Co Ltd, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Total revenue	2,856	2,660	2,079	4,184	4,603	4,661
Cost of revenue	1,237	1,023	836	1,344	1,291	1,243
Gross profit	1,619	1,637	1,243	2,839	3,312	3,417
Selling, general & administrative expenses	907	1,056	1,493	2,135	1,813	1,770
Research & development	277	333	675	993	780	878
Depreciation/amortization	105	135	210	257	261	151
Interest expense (income), operating	−14.4	6.0	40.4	–	–	–
Unusual expense (income)	−294	−75.5	1,157	172	−2.1	170
Other operating expenses	−38.5	−9.1	13.2	−137	−35.5	−195
Operating income	676	192	−2,345	−580	495	643
Net interest income (expense)	−44.1	−74.6	210	219	187	59.9
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	632	117	−2,135	−361	682	703
Provision for taxes	−41.1	−40.2	−54.1	367	348	371
Minority interest	–	0	−0.3	167	130	175
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	673	158	−2,082	−561	464	508
Extraordinary items	–	–	–	–	–	–
Net income	673	158	−2,082	−561	464	508
EBIT, normalized	368	123	−1,148	−408	493	813
EBITDA, normalized	499	293	−899	−97.0	808	1,018
Basic EPS, normalized	1.70	0.40	−5.07	−1.38	1.10	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Sumitomo Pharma Co Ltd, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Assets
Cash & short-term investments	313	266	239	1,232	1,961	2,016
Receivables	849	518	643	743	1,245	1,229
Total inventory	538	628	762	711	814	833
Prepaid expenses	–	–	–	–	–	–
Other current assets	59.9	275	138	190	85.6	75.4
Total current assets	1,760	1,688	1,782	2,876	4,106	4,154
Property, plant & equipment	279	311	383	444	527	587
Goodwill	1,330	1,316	1,320	1,577	1,604	1,594
Intangibles	1,011	1,150	1,293	2,480	3,277	3,463
Long-term investments	511	332	1,069	1,009	952	1,744
Note receivable	45.6	45.1	45.2	45.5	45.5	60.8
Other long-term assets	133	109	106	114	240	214
Total assets	5,069	4,952	5,998	8,545	10,751	11,817
Liabilities
Accounts payable	76.1	61.5	137	101	185	236
Payable/accrued	–	–	–	–	–	–
Accrued expenses	–	–	–	–	–	–
Short-term debt	240	283	1,154	682	41.3	45.2
Current portion of long-term debt	12.1	49.0	758	35.1	212	99.5
Other current liabilities	1,382	1,211	1,358	1,988	1,850	2,132
Total current liabilities	1,711	1,605	3,407	2,807	2,288	2,513
Long-term debt	1,160	1,764	916	1,891	2,092	2,489
Minority interest	–	–	0.5	0.2	540	611
Other liabilities	356	454	643	784	835	960
Total liabilities	3,227	3,822	4,966	5,482	5,755	6,572
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	141	149	148	169	184	202
Additional paid-in capital	–	–	–	–	137	143
Retained earnings (accumulated deficit)	1,002	312	−150	2,116	4,227	4,595
Treasury stock	−4.3	−4.5	−4.5	−5.1	−5.6	−6.1
Other equity	704	673	1,038	783	454	310
Total equity	1,843	1,130	1,031	3,063	4,997	5,245
Total liabilities & shareholders' equity	5,069	4,952	5,998	8,545	10,751	11,817

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Sumitomo Pharma Co Ltd, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Operating activities
Net income	673	158	−2,081	−728	334	333
Depreciation, depletion & amortization	131	170	250	311	315	205
Deferred taxes	–	–	–	–	–	–
Non-cash items	−237	−118	783	656	410	472
Changes in working capital	−32.6	−188	−543	−158	−802	216
Cash from operations	535	22.2	−1,591	81.3	257	1,225
Investing activities
Capital expenditures	−46.1	−86.9	−104	−96.0	−111	−97.6
Other investing cash flows	188	752	322	491	−39.3	178
Cash from investing	142	665	218	395	−150	80.2
Financing activities
Financing cash flow items	−2.0	3.8	4.4	−1,487	−7.2	−157
Cash dividends paid	0	0	−18.5	−83.8	−91.5	−100
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−573	−730	529	465	−77.5	−260
Cash from financing	−575	−726	515	−1,106	−176	−517
Foreign exchange effects	31.7	−1.2	102	181	146	42.7
Net change in cash	134	−39.6	−756	−448	76.3	831
Free cash flow	489	−64.7	−1,695	−14.6	146	1,127

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.